Voriconazole in the management of invasive aspergillosis in two patients with acute myeloid leukemia undergoing stem cell transplantation

被引：18

作者：

Mattei, D

Mordini, N

Lo Nigro, C

Ghirardo, D

Ferrua, MT

Osenda, M

Gallamini, A

Bacigalupo, A

Viscoli, C

机构：

[1] Osped S Croce, Div Ematol, Dept Hematol, I-12100 Cuneo, Italy

[2] Osped S Croce, Dept Radiol, I-12100 Cuneo, Italy

[3] Osped S Croce, Dept Lab, I-12100 Cuneo, Italy

[4] San Martino Hosp, Dept Hematol, Genoa, Italy

[5] Natl Canc Inst, Genoa, Italy

来源：

BONE MARROW TRANSPLANTATION | 2002年 / 30卷 / 12期

关键词：

acute myeloid leukemia; invasive aspergillosis; voriconazole; stem cell transplantation;

D O I：

10.1038/sj.bmt.1703763

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

The management of invasive aspergillosis in patients with hematological malignancies remains controversial. A major problem is how to manage patients who had invasive aspergillosis during remission induction and consolidation therapy and then undergo SCT. Indeed in these patients the mortality rate related to invasive aspergillosis recurrence remains unacceptably high. We report two cases of patients who underwent remission induction for AML, developed invasive aspergillosis during antifungal prophylaxis with itraconazole, failed amphotericin B deoxycholate and liposomal amphotericin B treatment, were successfully treated with voriconazole and eventually underwent SCT with voriconazole prophylaxis without reactivation of invasive aspergillosis.

引用

页码：967 / 970

页数：4

共 26 条

[1] Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].